A Phase IIa Trial of TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO): A Double-masked, Randomized Trial to Evaluate Efficacy and Tolerability
Phase of Trial: Phase II
Latest Information Update: 04 May 2018
At a glance
- Drugs Dexamethasone (Primary)
- Indications Retinal oedema
- Focus Therapeutic Use
- Sponsors Taiwan Liposome Company
- 30 Apr 2018 Status changed from recruiting to suspended due to strategic review of unblinded data to optimize doses
- 23 Apr 2018 Planned End Date changed from 1 Apr 2019 to 1 Jan 2020.
- 23 Apr 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Dec 2019.